Boosting multiregional clinical trials (MRCT) in Asia through the establishment of the Japan-led network for clinical research, the ARO alliance for ASEAN & East Asia (ARISE)

Miwa Sonoda; Maria Ruriko Umano Urbiztondo; Marlinang Diarta Siburian; Nattha Kerdsakundee; Sifa Marie Joelle Muchanga; Tatsuo Iiyama

doi:10.35772/ghm.2022.01007

この記事には本公開記事があります。本公開記事を参照してください。
引用する場合も本公開記事を引用してください。

Boosting multiregional clinical trials (MRCT) in Asia through the establishment of the Japan-led network for clinical research, the ARO alliance for ASEAN & East Asia (ARISE)

Miwa Sonoda, Maria Ruriko Umano Urbiztondo, Marlinang Diarta Siburian, Nattha Kerdsakundee, Sifa Marie Joelle Muchanga, Tatsuo Iiyama

著者情報

キーワード: clinical research, clinical trial, global health, Asia

ジャーナルフリー早期公開

論文ID: 2022.01007

DOI https://doi.org/10.35772/ghm.2022.01007

この記事には本公開記事があります。

The final version of this article is now available: Vol. 4 (2022), No. 4 pp. 247-249

詳細

抄録

There is an increasing demand for clinical research, and this demand has particularly increased during the novel coronavirus infection (COVID-19) pandemic. In the light of these events, fostering international cooperation has become essential. The ARO Alliance for ASEAN & East Asia (ARISE) is a Japan-led international network for clinical research in Asia that was established to encourage and facilitate multiregional clinical trials. The Department of International Trials of the National Center for Global Health and Medicine (NCGM) launched ARISE in December 2021 to pursue efficacious, high-quality clinical research and ensure rapid responses to health emergencies, with the timely provision of new medicinal products to patients in Asia.

責任著者(Corresponding author)

J-STAGEへの登録はこちら（無料）